A hemangioma is a benign tumor of cells that line blood vessels, appearing during the first few weeks of life as a large birthmark or lesion. A study published in Pediatric Dermatology reveals that a disturbance of oxygen depletion was found in placentas of babies who developed infantile hemangioma (IH).

Researchers at the Stanford University School of Medicine have isolated a human blood cell that represents the great-grandparent of all the cells of the blood, a finding that could lead to new treatments for blood cancers and other blood diseases.

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.

Scientists here have found that mini-molecules called micro-RNA may play a critical role in the progression of chronic myeloid leukemia (CML) from its more treatable chronic phase to a life-threatening phase, called blast crisis.

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

An international panel of researchers led by an oncologist from the Duke Comprehensive Cancer Center has put together a set of guidelines for the prevention and treatment of dangerous blood clots that threaten cancer patients.

A number of cases of a rare blood cancer has increased in northeastern Pennsylvania. The federal government didn't find any possible reason in the environment.

In the November 1st issue of G&D, Dr. Michael Cleary (Stanford University School of Medicine) and colleagues identify the gene Meis1 as a critical player in the establishment of leukemia stem cells, and the development of MLL leukemia.

A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.

A novel strategy to hopefully beat into oblivion one of the most aggressive forms of acute myelogenous leukemia combines the strengths of some of the newest leukemia agents, researchers say.

Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).

All blood cell production in adults depends on the steady work of a vital gene that if lost results in early bone marrow failure, Dartmouth Medical School cancer geneticists have found. Their research reveals an unexpected role for the gene in sustaining the adult blood-forming system, and opens novel strategies for targeting the gene, which is often involved in a type of childhood leukemia.